Tatva Chintan Pharma Chem Limited (NSE:TATVA)
India · Delayed Price · Currency is INR 1,115.10
-51.90 (-4.45%)
Aug 1, 2025, 3:29 PM IST
Tatva Chintan Pharma Chem Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2019 - 2021 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2019 - 2021 |
| 3,941 | 3,827 | 3,935 | 4,236 | 4,336 | 3,004 | Upgrade | |
Revenue Growth (YoY) | 2.47% | -2.74% | -7.11% | -2.31% | 44.38% | 14.10% | Upgrade |
Cost of Revenue | 2,003 | 1,989 | 1,830 | 2,327 | 2,015 | 1,574 | Upgrade |
Gross Profit | 1,938 | 1,838 | 2,105 | 1,910 | 2,321 | 1,430 | Upgrade |
Selling, General & Admin | 543.07 | 529.16 | 563.05 | 430.87 | 319.58 | 252.51 | Upgrade |
Other Operating Expenses | 1,006 | 966.44 | 848.1 | 798.39 | 915.23 | 508.18 | Upgrade |
Operating Expenses | 1,849 | 1,772 | 1,667 | 1,325 | 1,317 | 828.02 | Upgrade |
Operating Income | 89.63 | 65.54 | 437.83 | 584.69 | 1,005 | 601.81 | Upgrade |
Interest Expense | -13.89 | -12.9 | -61.51 | -79.97 | -43.51 | -39.85 | Upgrade |
Interest & Investment Income | - | - | 23.96 | 38.38 | 45.4 | 2.77 | Upgrade |
Currency Exchange Gain (Loss) | - | - | 28.15 | -72.9 | 38.41 | 37.53 | Upgrade |
Other Non Operating Income (Expenses) | 22.97 | 23.15 | 5.22 | 10.89 | -4.15 | 3.84 | Upgrade |
EBT Excluding Unusual Items | 98.71 | 75.79 | 433.65 | 481.09 | 1,041 | 606.1 | Upgrade |
Gain (Loss) on Sale of Investments | - | - | 1.89 | - | - | - | Upgrade |
Gain (Loss) on Sale of Assets | - | - | -1.48 | -0.01 | -0.51 | -0.34 | Upgrade |
Other Unusual Items | - | - | 1.62 | -35.43 | 0.73 | - | Upgrade |
Pretax Income | 98.71 | 75.79 | 435.68 | 445.65 | 1,041 | 605.76 | Upgrade |
Income Tax Expense | 27.16 | 18.66 | 132.14 | -9.22 | 82.47 | 83.14 | Upgrade |
Net Income | 71.55 | 57.13 | 303.54 | 454.87 | 958.74 | 522.62 | Upgrade |
Net Income to Common | 71.55 | 57.13 | 303.54 | 454.87 | 958.74 | 522.62 | Upgrade |
Net Income Growth | -72.54% | -81.18% | -33.27% | -52.55% | 83.45% | 38.30% | Upgrade |
Shares Outstanding (Basic) | 23 | 23 | 23 | 22 | 21 | 20 | Upgrade |
Shares Outstanding (Diluted) | 23 | 23 | 23 | 22 | 21 | 20 | Upgrade |
Shares Change (YoY) | 1.02% | 2.29% | 3.27% | 3.10% | 7.03% | - | Upgrade |
EPS (Basic) | 3.05 | 2.44 | 13.26 | 20.52 | 44.59 | 26.02 | Upgrade |
EPS (Diluted) | 3.05 | 2.44 | 13.26 | 20.52 | 44.59 | 26.02 | Upgrade |
EPS Growth | -72.82% | -81.60% | -35.38% | -53.98% | 71.39% | 38.32% | Upgrade |
Free Cash Flow | - | -516.01 | -304.71 | -1,753 | -689.27 | -12.74 | Upgrade |
Free Cash Flow Per Share | - | -22.04 | -13.31 | -79.10 | -32.06 | -0.63 | Upgrade |
Dividend Per Share | - | 1.000 | 2.000 | 2.000 | 2.000 | 5.000 | Upgrade |
Dividend Growth | - | -50.00% | - | - | -60.00% | 150.00% | Upgrade |
Gross Margin | 49.18% | 48.02% | 53.50% | 45.08% | 53.53% | 47.60% | Upgrade |
Operating Margin | 2.27% | 1.71% | 11.13% | 13.80% | 23.17% | 20.04% | Upgrade |
Profit Margin | 1.81% | 1.49% | 7.71% | 10.74% | 22.11% | 17.40% | Upgrade |
Free Cash Flow Margin | - | -13.48% | -7.74% | -41.39% | -15.90% | -0.42% | Upgrade |
EBITDA | 372.49 | 342.13 | 689.34 | 676.3 | 1,083 | 666.37 | Upgrade |
EBITDA Margin | 9.45% | 8.94% | 17.52% | 15.96% | 24.98% | 22.19% | Upgrade |
D&A For EBITDA | 282.86 | 276.59 | 251.51 | 91.61 | 78.45 | 64.56 | Upgrade |
EBIT | 89.63 | 65.54 | 437.83 | 584.69 | 1,005 | 601.81 | Upgrade |
EBIT Margin | 2.27% | 1.71% | 11.13% | 13.80% | 23.17% | 20.04% | Upgrade |
Effective Tax Rate | 27.52% | 24.62% | 30.33% | - | 7.92% | 13.73% | Upgrade |
Revenue as Reported | 3,964 | 3,850 | 4,010 | 4,294 | 4,427 | 3,056 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.